These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11772767)

  • 1. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women.
    Cook JA; Cohen MH; Grey D; Kirstein L; Burke J; Anastos K; Palacio H; Richardson J; Wilson TE; Young M
    Am J Public Health; 2002 Jan; 92(1):82-7. PubMed ID: 11772767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women.
    Cook JA; Cohen MH; Burke J; Grey D; Anastos K; Kirstein L; Palacio H; Richardson J; Wilson T; Young M
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):401-9. PubMed ID: 12138346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS).
    Navazesh M; Mulligan R; Karim R; Mack WJ; Ram S; Seirawan H; Greenspan J; Greenspan D; Phelan J; Alves M;
    Oral Dis; 2009 Jan; 15(1):52-60. PubMed ID: 19017280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.
    Silverberg MJ; Gore ME; French AL; Gandhi M; Glesby MJ; Kovacs A; Wilson TE; Young MA; Gange SJ
    Clin Infect Dis; 2004 Sep; 39(5):717-24. PubMed ID: 15356788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
    Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
    Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
    Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.
    Kapadia F; Cook JA; Cohen MH; Sohler N; Kovacs A; Greenblatt RM; Choudhary I; Vlahov D
    Addiction; 2005 Jul; 100(7):990-1002. PubMed ID: 15955015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of oral lesions in HIV-1-infected women: reduction with HAART.
    Greenspan D; Gange SJ; Phelan JA; Navazesh M; Alves ME; MacPhail LA; Mulligan R; Greenspan JS
    J Dent Res; 2004 Feb; 83(2):145-50. PubMed ID: 14742653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.